Navigation Links
NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results

FT. MYERS, Fla., March 5 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM), an operator of a network of cancer-focused testing laboratories, today announced its results for the fourth quarter and full-year ended December 31, 2008.

Fourth Quarter 2008 Highlights:

  • Revenue of $5.9 million, an increase of 56% year-over-year from Q4 07
  • 17.2% sequential increase in revenues in Q4 08 vs. Q3 08
  • Avg. Rev/Requisition increased 13.7% in Q4 08 from Q4 07
  • Avg. Rev/Test increased 9.6% in Q4 08 from Q4 07
  • Development of in-house molecular testing capability

Fiscal Year 2008 Highlights:

  • Revenue of $20.0 million, an increase of 74% year-over-year from FY 07
  • Avg. Rev/Requisition increased 15% in FY 08 from FY 07
  • Avg. Rev/Test increased 12.3% in FY 08 from FY 07
  • Days Sales Outstanding (DSO) declined to 45 days on 12/31/08 from 79 on 12/31/07

Fourth Quarter 2008

Revenues increased 56.0% year-over-year to $5.9 million in Q4 08 from Q4 07. Requisitions increased 37.2% and average revenue/requisition increased 13.7% to $819.77. Gross profit increased 65.8% to approximately $3.1 million in Q4 08. Gross profit margin increased by 310 basis points to 53.1% in Q4 08 from 50.0% in Q4 07. Selling, general and administrative ("SG&A") expenses increased 11.0% to approximately $3.8 million. However, SG&A expenses as a percentage of revenue fell to 64.8% in Q4 08 from 91.1% in Q4 07. Net loss decreased by approximately $601,000 to ($994,000) or ($0.03)/share in Q4 08 from ($1,596,000) or ($0.05/share) in Q4 07.

SG&A expenses in the fourth quarter included the write-off of approximately $318,000 of previously capitalized transaction expenses incurred in connection with exploring a strategic transaction which we ultimately determined was not in our shareholders' best interests to consummate. Fourth quarter SG&A also includes a charge of $200,000 to fully reserve for potential losses in our investment in Power3 Medical Products, Inc. Based on Power 3's February 19th 8-K filing and recent conversations with their management team, we have concluded that it is more likely than not that we will be unable to realize any value from this investment. We also took approximately $415,000 of incremental bad debt expense in Q4 08 over and above what we took in Q3 08 in order to write off the rest of the accounts receivable balance left in our previous billing system, which was replaced in March 2008, and provide for a more adequate reserve balance against our current receivables in light of the current economic conditions. Absent these expenses, we would have been approximately break-even in the fourth quarter and our SG&A as a percentage of revenue would have been in-line with the trend we reported in Q3 08.

Robert Gasparini, the Company's President and Chief Scientific Officer, stated, "We continue to be very pleased with the momentum in our business. 2008 was the second year in a row that we were able to grow our revenues by approximately 75% and we accomplished much during the year, including rolling out many new products, growing our sales force considerably and achieving near break-even in our cash flow from operations. Although our fourth quarter included a number of unusual expense items which adversely impacted our bottom-line, our business is very strong on a current operating basis. As we have seen in our industry, it takes approximately $2.0 - $2.5 million of monthly revenues to derive any real operating leverage. Now that we have reached that threshold, we expect to be able to invest a much larger portion of our incremental revenue into sales and marketing initiatives. Indeed, we believe we have now concluded the most difficult part of our corporate evolution and are very much looking forward to Phase II of the Company's development, which we expect will begin with robust and profitable growth in 2009."

Mr. Gasparini continued, "I am also pleased to report that in Q4 we began performing molecular genetic testing in-house. During Q4, we brought up and validated both the BCR/ABL and JAK2 molecular tests and began to offer them to clients. Although molecular testing volumes are currently modest, by bringing this capability in-house, we are able to save on the significant costs of sending these types of tests out. During 2009, we expect to bring up another 6-8 molecular tests. During Q4, we also made significant strides in further developing our in-house immunohistochemistry product line. We validated over 100 antibodies and have already grown this business to approximately $100,000/month in revenue. We are also in the process of developing a number of other new product line extensions which we expect to begin launching later this year."

Full Year 2008

For the full-year of 2008, revenues increased by $8.5 million or 74.0% to $20.0 million from $11.5 million in 2007. Requisitions increased by 51.2% and average revenue/requisition increased by 15.0%. Gross profit increased by 78.2% or approximately $4.7 million to approximately $10.7 million in the full-year of 2008. SG&A expenses increased 26.6% to approximately $11.5 million for the full-year of 2008. The increases in SG&A are primarily the result of adding sales and marketing and corporate personnel to continue to scale our business. SG&A as a percentage of revenue fell to 57.7% for the full-year of 2008 from 79.3% in the comparable period in 2007. Net loss decreased by approximately $1,998,000 to ($1,383,000) or ($0.04/share) for the full-year of 2008 from ($3,380,173) or ($0.11/share) for the comparable period in 2007.

Conference Call

The Company has scheduled a webcast and conference call to discuss their Q4 and full year 2008 results at 11:00 AM EST today. Interested investors should dial (877) 407-8033 (domestic) and (201) 689-8033 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on March 12, 2009 and can be accessed by dialing (877) 660-6853 (domestic) and 1(201) 612-7415 (international). The playback conference ID Number is 315878 and the PIN Number is 286. The web-cast may be accessed under the Investor Relations section of our website at or at An archive of the web-cast will be available until 11:59 PM EST on March 6, 2010.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. For additional information about NeoGenomics, visit

Interested parties can also access additional investor relations material from the American Microcap Institute at or from Hawk Associates at An investment profile about NeoGenomics may be found at

Forward Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements, Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

                           NeoGenomics, Inc.

                          CONSOLIDATED BALANCE SHEET AS OF
                       December 31, 2008 and December 31, 2007

    ASSETS                                   December 31,      December 31,
                                                2008               2007

      Cash and cash equivalents                $468,171          $210,573

      Accounts Receivable (net of allowance
       for doubtful accounts of $358,642 and
       $414,548, respectively)                2,913,531         3,236,751

      Other Current Assets                    1,324,416           704,918

    TOTAL CURRENT ASSETS                      4,706,118         4,152,242

     accumulated depreciation of $1,602,594
     and $862,030, respectively)              2,875,297         2,108,083

    OTHER ASSETS                                 64,509           260,575

        TOTAL                                $7,645,924        $6,520,900


    CURRENT LIABILITIES                      $4,390,994        $3,361,705

    LONG TERM LIABILITIES                     1,403,271           837,081

        TOTAL LIABILITIES                     5,794,265         4,198,786

    STOCKHOLDERS' EQUITY                      1,851,659         2,322,114

        TOTAL                                $7,645,924        $6,520,900

                                  NeoGenomics, Inc.


                          For the       For the       For the      For the
                        Twelve-Months Twelve-Months Three-Months Three-Months
                            Ended         Ended         Ended       Ended
                          December      December      December    December
                          31, 2008      31, 2007      31, 2008    31, 2007

    REVENUE              $20,015,319  $11,504,725  $5,920,360   $3,795,316

    COST OF REVENUE        9,353,852    5,522,775   2,776,302    1,898,914

    GROSS PROFIT          10,661,467    5,981,950   3,144,058    1,896,402

    Selling, general
     and administrative   11,545,456    9,122,922   3,839,172    3,458,869
       Total operating
        expenses          11,545,456    9,122,922   3,839,172    3,458,869

    Income (loss) from
     operations             (883,989)  (3,140,972)   (695,114)  (1,562,467)

    Other income (loss)
    Interest income/
     (expense), net         (298,597)    (239,200)    (99,261)     (33,395)
    Loss on investments     (200,000)           -    (200,000)           -
    Other Income (loss)     (498,597)    (239,200)   (299,261)     (33,395)

    NET INCOME (LOSS)    $(1,382,586) $(3,380,172)  $(994,375) $(1,595,862)

     PER SHARE - Basic
     and Diluted              $(0.04)      $(0.11)     $(0.03)      $(0.05)

     Basic and Diluted    31,506,824   29,764,289  31,870,605   31,374,096

                                    NeoGenomics, Inc.


                                                  For the         For the
                                               Twelve-Months   Twelve-Months
                                                   Ended           Ended
                                                December 31,    December 31,
                                                    2008            2007

    NET CASH USED IN OPERATING ACTIVITIES          $(273,673)   $(2,642,591)

    NET CASH USED IN INVESTING ACTIVITIES           (501,781)      (716,144)

    NET CASH PROVIDED BY FINANCING ACTIVITIES      1,173,184      3,443,042

                  AND CASH EQUIVALENTS               397,730         84,307

     PERIOD                                          210,573        126,266

    CASH AND CASH EQUIVALENTS, END OF PERIOD        $608,303       $210,573


      Interest paid                                 $256,323       $204,670

      Income taxes paid                                   $-             $-


         Equipment leased under capital lease     $1,207,863       $703,145

                                 NeoGenomics, Inc.

            Supplemental Information on Customer Requisitions Received
                                and Tests Performed

                        For the    For the            For the   For the
                        Twelve-    Twelve-            Three-    Three-
                        Months     Months             Months    Months
                        Ended      Ended              Ended     Ended
                        Dec 31,    Dec 31, % Inc      Dec 31,   Dec 31, % Inc
                        2008       2007    (Dec)      2008      2007    (Dec)

     Rec'd (Cases)     24,780      16,385  51.2%      7,222      5,262  37.2%
    # of Tests
     Performed         32,539      20,998  55.0%      9,490      6,666  42.4%
    Avg. # of
     Tests / Case        1.31        1.28   2.3%       1.31       1.27   3.7%

     Revenue      $20,015,319 $11,504,725  74.0% $5,920,360 $3,795,317  56.0%
    Avg Revenue/
     Requisition      $807.72     $702.15  15.0%    $819.77    $721.27  13.7%
    Avg Revenue/
     Test             $615.12     $547.90  12.3%    $623.85    $569.35   9.6%

SOURCE NeoGenomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
2. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
3. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
4. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
5. NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10
6. NeoGenomics Schedules its Q4 and Full Year 2008 Earnings Release for March 5, 2009
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... The award-winning ... to broadcast first quarter 2018. American Farmer airs Tuesdays at 8:30aET on RFD-TV. ... is faced with the challenge of how to continue to feed a growing nation. ...
(Date:10/7/2017)... ... October 06, 2017 , ... Phase ... metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers can ... Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ProxiMeta ...
Breaking Biology Technology:
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):